Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetes
NCT02129985Phase 4Unknown
- Start
- Feb 2014
- Primary completion
- Jun 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Time to glycaemic remission at 1 year and Remission rate of type 2 diabetes at 1 year. Status: unknown.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02129985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129985.